Scroll

dobutamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
dopaminergic agents dopamine derivatives used as cardiac stimulant/antihypertensives/diuretics	937	34368-04-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: dobutamine dobutamine hydrochloride dobutamine HCl	A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY. Molecular weight: 301.39 Formula: C18H23NO3 CLOGP: 2.43 LIPINSKI: 0 HAC: 4 HDO: 4 TPSA: 72.72 ALOGS: -4.34 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

dobutamine
dobutamine hydrochloride
dobutamine HCl

A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY.

Molecular weight: 301.39
Formula: C18H23NO3
CLOGP: 2.43
LIPINSKI: 0
HAC: 4
HDO: 4
TPSA: 72.72
ALOGS: -4.34
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.50	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.10 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.13 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
CL (Clearance)	115 mL/min/kg	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
July 18, 1978	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Stress cardiomyopathy	158.04	29.35	44	3020	8292	56280711
Cardiogenic shock	136.77	29.35	46	3018	16279	56272724
Multiple organ dysfunction syndrome	81.98	29.35	45	3019	52725	56236278
Cardiac failure	75.56	29.35	50	3014	82043	56206960
Drug ineffective	66.43	29.35	150	2914	918839	55370164
Local anaesthetic systemic toxicity	56.52	29.35	12	3052	722	56288281
Pulmonary hypertension	38.20	29.35	24	3040	35920	56253083
Septic shock	37.35	29.35	29	3035	60806	56228197
Ureaplasma infection	36.70	29.35	8	3056	545	56288458
Ventricular tachycardia	36.50	29.35	18	3046	16883	56272120
Status epilepticus	35.32	29.35	17	3047	15124	56273879
Hypotension	34.23	29.35	54	3010	250454	56038549
Renal impairment	34.08	29.35	31	3033	80682	56208321
Renal failure	32.79	29.35	35	3029	110465	56178538
Ventricular fibrillation	30.82	29.35	14	3050	10938	56278065

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Appendicolith	426.91	30.39	113	5246	5618	31686367
Cardiogenic shock	426.22	30.39	155	5204	22253	31669732
Appendicitis	357.70	30.39	115	5244	11350	31680635
Multiple organ dysfunction syndrome	345.62	30.39	186	5173	68017	31623968
Stress	314.52	30.39	128	5231	24813	31667172
Ascites	236.03	30.39	122	5237	40891	31651094
Ventricular fibrillation	221.31	30.39	92	5267	18756	31673229
Abdominal distension	198.52	30.39	117	5242	50567	31641418
Hyponatraemia	153.89	30.39	115	5244	73684	31618301
Sepsis	141.85	30.39	150	5209	151779	31540206
General physical health deterioration	141.06	30.39	131	5228	113304	31578681
Constipation	100.83	30.39	114	5245	123877	31568108
Blood phosphorus increased	96.19	30.39	34	5325	4448	31687537
Abdominal pain	90.57	30.39	117	5242	145835	31546150
Off label use	86.38	30.39	184	5175	347090	31344895
Toxic epidermal necrolysis	81.31	30.39	47	5312	19477	31672508
Vomiting	56.91	30.39	120	5239	223853	31468132
Drug ineffective	55.54	30.39	169	5190	395404	31296581
Stress cardiomyopathy	51.81	30.39	17	5342	1773	31690212
Platelet distribution width increased	50.28	30.39	10	5349	133	31691852
Ventricular tachycardia	42.79	30.39	34	5325	23667	31668318
Right ventricular failure	34.62	30.39	20	5339	8262	31683723
Nausea	34.42	30.39	122	5237	307825	31384160
Fear	31.18	30.39	20	5339	9954	31682031

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cardiogenic shock	563.06	28.61	195	7874	36112	70884263
Appendicolith	466.80	28.61	112	7957	5568	70914807
Multiple organ dysfunction syndrome	397.04	28.61	209	7860	108306	70812069
Appendicitis	355.23	28.61	114	7955	16619	70903756
Ventricular fibrillation	265.60	28.61	104	7965	27007	70893368
Stress	245.55	28.61	130	7939	67836	70852539
Ascites	243.46	28.61	129	7940	67418	70852957
Abdominal distension	181.60	28.61	125	7944	104544	70815831
Stress cardiomyopathy	180.10	28.61	60	8009	9802	70910573
Sepsis	154.15	28.61	163	7906	244382	70675993
Hyponatraemia	117.58	28.61	116	7953	159971	70760404
Drug ineffective	113.57	28.61	295	7774	939457	69980918
General physical health deterioration	112.23	28.61	136	7933	235895	70684480
Blood phosphorus increased	107.12	28.61	37	8032	6733	70913642
Off label use	96.50	28.61	240	7829	742820	70177555
Constipation	82.28	28.61	121	7948	252317	70668058
Toxic epidermal necrolysis	75.03	28.61	50	8019	39507	70880868
Ventricular tachycardia	73.85	28.61	48	8021	36375	70884000
Fatigue	66.54	28.61	8	8061	824311	70096064
Cardiac failure	65.31	28.61	81	7988	143460	70776915
Abdominal pain	61.41	28.61	126	7943	342001	70578374
Platelet distribution width increased	54.16	28.61	10	8059	134	70920241
Right ventricular failure	49.22	28.61	31	8038	22243	70898132
Local anaesthetic systemic toxicity	45.75	28.61	12	8057	853	70919522
Shock	38.67	28.61	34	8035	40391	70879984
Arthralgia	37.90	28.61	6	8063	503384	70416991
Hypernatraemia	36.58	28.61	21	8048	12740	70907635
Renal impairment	35.72	28.61	61	8008	143876	70776499
Renal injury	34.55	28.61	22	8047	16072	70904303
Fear	33.99	28.61	24	8045	20787	70899588
Cardiomyopathy	33.18	28.61	26	8043	26347	70894028
Vasoplegia syndrome	30.48	28.61	12	8057	3144	70917231
Renal failure	29.63	28.61	66	8003	189004	70731371
Myocardial calcification	29.00	28.61	5	8064	44	70920331
Electrocardiogram ST segment elevation	28.67	28.61	15	8054	7589	70912786

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C01CA07	CARDIOVASCULAR SYSTEM CARDIAC THERAPY CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES Adrenergic and dopaminergic agents
FDA MoA	N0000000245	Adrenergic beta-Agonists
FDA EPC	N0000175555	beta-Adrenergic Agonist
CHEBI has role	CHEBI:35522	beta-adrenergic agonists
CHEBI has role	CHEBI:35524	sympathomimetic
CHEBI has role	CHEBI:38147	cardiotonic drugs
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D000322	Adrenergic Agonists
MeSH PA	D058665	Adrenergic beta-1 Receptor Agonists
MeSH PA	D000318	Adrenergic beta-Agonists
MeSH PA	D002316	Cardiotonic Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D020011	Protective Agents
MeSH PA	D013566	Sympathomimetics

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Cardiogenic shock	indication	89138009
Decompensated cardiac failure	indication	195111005
Stress echocardiography using dobutamine	indication	703338002
Cardiac Decompensation	indication
Cardiac Decompensation Post Cardiac Surgery	indication
Organic Cardiac Disease	indication
Ventricular premature beats	contraindication	17338001
Myocardial infarction	contraindication	22298006	DOID:5844
Hypovolemia	contraindication	28560003
Hypertensive disorder	contraindication	38341003	DOID:10763
Hypokalemia	contraindication	43339004
Atrial fibrillation	contraindication	49436004	DOID:0060224
Aortic valve stenosis	contraindication	60573004	DOID:1712
Idiopathic hypertrophic subaortic stenosis	contraindication	360465008

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.98	acidic
pKa2	10.59	acidic
pKa3	13.49	acidic
pKa4	9.03	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN	AGONIST	EC50	5.50	WOMBAT-PK	CHEMBL
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN	AGONIST	EC50	6.20	WOMBAT-PK	CHEMBL
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	5.98	DRUG MATRIX
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	6.00	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	6.42	DRUG MATRIX
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	5.87	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	5.77	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	6.91	DRUG MATRIX
Carbonic anhydrase 2	Enzyme	P00918	CAH2_HUMAN		Ki	6.32	CHEMBL
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	7.35	DRUG MATRIX
Carbonic anhydrase 1	Enzyme	P00915	CAH1_HUMAN		Ki	5.72	CHEMBL
Carbonic anhydrase 4	Enzyme	P22748	CAH4_HUMAN		Ki	5.05	CHEMBL
Carbonic anhydrase 9	Enzyme	Q16790	CAH9_HUMAN		Ki	5.01	CHEMBL
Carbonic anhydrase 12	Enzyme	O43570	CAH12_HUMAN		Ki	5.36	CHEMBL
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN		IC50	5.26	DRUG MATRIX
Carbonic anhydrase 5A, mitochondrial	Enzyme	P35218	CAH5A_HUMAN		Ki	6.14	CHEMBL
Carbonic anhydrase 5B, mitochondrial	Enzyme	Q9Y2D0	CAH5B_HUMAN		Ki	6.05	CHEMBL
Carbonic anhydrase 7	Enzyme	P43166	CAH7_HUMAN		Ki	5.37	CHEMBL
Tyrosine-protein kinase Lck	Kinase	P06239	LCK_HUMAN		IC50	5.26	DRUG MATRIX
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN		IC50	5.40	DRUG MATRIX
Catechol O-methyltransferase	Enzyme	P21964	COMT_HUMAN		Km	4.30	WOMBAT-PK
Carbonic anhydrase 3	Enzyme	P07451	CAH3_HUMAN		Ki	5.13	CHEMBL
Carbonic anhydrase 6	Enzyme	P23280	CAH6_HUMAN		Ki	5.02	CHEMBL
Carbonic anhydrase 14	Enzyme	Q9ULX7	CAH14_HUMAN		Ki	4.92	CHEMBL
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	5.38	CHEMBL
Carbonic anhydrase 13	Enzyme	Q8N1Q1	CAH13_HUMAN		Ki	5.02	CHEMBL
Arachidonate 15-lipoxygenase	Enzyme		LOX15_RABIT		IC50	6.22	DRUG MATRIX
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	6.73	DRUG MATRIX
Membrane-associated progesterone receptor component 1	Membrane receptor		PGRC1_RAT		Ki	5.80	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	6.96	CHEMBL
Carbonic anhydrase 15	Enzyme		CAH15_MOUSE		Ki	6.41	CHEMBL

External reference:

ID	Source
4019730	VUID
N0000147822	NUI
D00632	KEGG_DRUG
49745-95-1	SECONDARY_CAS_RN
203121	RXNORM
4017541	VANDF
4019730	VANDF
C0012963	UMLSCUI
CHEBI:4670	CHEBI
Y00	PDB_CHEM_ID
CHEMBL926	ChEMBL_ID
DB00841	DRUGBANK_ID
CHEMBL1200418	ChEMBL_ID
D004280	MESH_DESCRIPTOR_UI
36811	PUBCHEM_CID
535	IUPHAR_LIGAND_ID
3340	INN_ID
3S12J47372	UNII
2871	MMSL
4625	MMSL
d00215	MMSL
000614	NDDF
000615	NDDF
26523005	SNOMEDCT_US
387145002	SNOMEDCT_US
90118002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Dobutamine Hydrochloride in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1073	INJECTION	100 mg	INTRAVENOUS	NDA	18 sections
Dobutamine Hydrochloride in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1075	INJECTION	200 mg	INTRAVENOUS	NDA	18 sections
Dobutamine Hydrochloride in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1077	INJECTION	400 mg	INTRAVENOUS	NDA	18 sections
DOBUTAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2344	INJECTION, SOLUTION, CONCENTRATE	12.50 mg	INTRAVENOUS	ANDA	21 sections
DOBUTAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2344	INJECTION, SOLUTION, CONCENTRATE	12.50 mg	INTRAVENOUS	ANDA	21 sections
Dobutamine in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2346	INJECTION, SOLUTION	100 mg	INTRAVENOUS	NDA	12 sections
Dobutamine in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2347	INJECTION, SOLUTION	200 mg	INTRAVENOUS	NDA	12 sections
Dobutamine in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0409-3724	INJECTION, SOLUTION	400 mg	INTRAVENOUS	NDA	12 sections
Dobutamine Hydrochloride in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4562	INJECTION	400 mg	INTRAVENOUS	NDA	18 sections
DOBUTAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1330	INJECTION, SOLUTION	200 mg	INTRAVENOUS	NDA	12 sections
DOBUTAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1337	INJECTION, SOLUTION, CONCENTRATE	12.50 mg	INTRAVENOUS	ANDA	12 sections
DOBUTAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1337	INJECTION, SOLUTION, CONCENTRATE	12.50 mg	INTRAVENOUS	ANDA	12 sections
DOBUTAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1566	INJECTION	100 mg	INTRAVENOUS	NDA	11 sections
Dobutamine	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5717	INJECTION, SOLUTION	12.50 mg	INTRAVENOUS	ANDA	11 sections
Dobutamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5777	INJECTION, SOLUTION	400 mg	INTRAVENOUS	NDA	12 sections